Although the xenograft model does not allow the evaluation of cartilage and bone erosions associated with RA, it does offer the unparalleled advantage of directly testing the effect of human-specific biologic agents, such as the anti-TNF adalimumab, on cellular infiltration and cytokine production in its natural human microenvironment, accelerating translation to the human disease. Here, TNF is linked to rheumatoid arthritis.